Neratinib after standard therapy for HER2-positive early breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial is testing whether adding neratinib after standard treatment helps prevent HER2-positive early breast cancer from coming back. It is open only to patients treated at Peking University People's Hospital.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HER2-positive breast cancer that was diagnosed at Peking University People's Hospital.
- You must have had a radical mastectomy (complete removal of the tumor) at that hospital.
- You must have already received standard anti-HER2 treatment like trastuzumab, pertuzumab, or T-DM1.
- You must agree to participate in the hospital's breast disease cohort study by signing a consent form.
- Your cancer must not have spread to other parts of the body (metastatic) or be in both breasts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding targeted therapy to chemotherapy after surgery can help prevent HER2-positive early breast cancer from coming back. It is for patients whose cancer has not spread to lymph nodes and who have certain tumor sizes and features.
This trial tests a taxane chemotherapy combined with a targeted therapy for women with early-stage, HER2-positive breast cancer that has not spread to lymph nodes. It aims to provide a tailored treatment based on tumor size and risk factors.
This trial tests whether combining chemotherapy with targeted therapy works better for women with high-risk, HER2 positive early breast cancer that hasn't spread to lymph nodes. If you've had surgery and your tumor fits certain high-risk features, you may be eligible to join.
This trial tests whether a short course of chemo plus two targeted drugs (trastuzumab and pertuzumab) before surgery works well for people with early-stage, low-risk HER2-positive breast cancer. It may help reduce the need for stronger chemo later.
This trial tests whether taking neratinib after completing a year of standard treatment can help prevent breast cancer from coming back in women who had a complete response to initial therapy but still have high-risk features.
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.